Press release
Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing
An investigation on behalf of current long term investors in Cytokinetics, Incorporated (NASDAQ: CYTK) shares.
Investors who are current long term investors in Cytokinetics, Incorporated (NASDAQ: CYTK) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: CYTK stocks follows a lawsuit filed against Cytokinetics, Incorporated over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CYTK stocks, concerns whether certain Cytokinetics, Incorporated directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 27, 2023, to May 6, 2025, the defendants created the false impression that aficamten had been completely and properly submitted as a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA"),and that in truth, the defendants had knowingly or recklessly omitted a Risk Evaluation and Mitigation Strategy ("REMS") from the initial NDA submission, despite prior FDA discussions about safety and risk mitigation, and that the subsequent REMS submission necessitated a three-month delay in the FDA's process for potential approval
Those who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
Web: www.shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing here
News-ID: 4384868 • Views: …
More Releases from Shareholders Foundation, Inc.
Long-Term Investors in shares of Molina Healthcare, Inc. (NYSE: MOH) should cont …
An investigation on behalf of current long-term investors in shares of Molina Healthcare, Inc. (NYSE: MOH concerning potential breaches of fiduciary duties by certain directors and officers of Molina Healthcare, Inc. was announced.
Investors who are current long term investors in Molina Healthcare, Inc. (NYSE: MOH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law…
Cepton, Inc. (formerly NASDAQ: CPTN) Investor Alert: Investigation of potential …
An investigation on behalf of investors in shares of Cepton, Inc. (formerly NASDAQ: CPTN) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Cepton, Inc. (formerly NASDAQ: CPTN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in formerly NASDAQ:…
Investigation announced for long term investors in shares of Spirit Aviation Hol …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Spirit Aviation Holdings, Inc.
Investors who are current long term investors in Spirit Aviation Holdings, Inc. (OTC: FLYYQ) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in OTC: FLYYQ stocks follows a…
ALERT: Lawsuit filed for Investors who lost money with shares of Bath & Body Wor …
An investor, who purchased shares of Bath & Body Works, Inc. (NYSE: BBWI), filed a lawsuit over alleged violations of Federal Securities Laws by Bath & Body Works, Inc.
Investors who purchased shares of Bath & Body Works, Inc. (NYSE: BBWI) have certain options and for certain investors are short and strict deadlines running. Deadline: March 16, 2026. NYSE: BBWI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
More Releases for Cytokinetics
Lawsuit filed for Investors who lost money with shares of Cytokinetics, Incorpor …
An investor, who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK), filed a lawsuit over alleged violations of Federal Securities Laws by Cytokinetics, Incorporated in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK) have certain options and for certain investors are short and strict deadlines running. Deadline: November 17, 2025. NASDAQ: CYTK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Expands with Gene-Based Re …
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
Hypertrophic Cardiomyopathy Therapeutics Market is expected to grow from USD 1.1 billion in 2025 to USD 2.3 billion by 2032, exhibiting a CAGR of 11.2% during the forecast period.
The latest report (2025-2032) on the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market by Coherent Market Insights offers an in-depth analysis of market trends, growth factors, challenges, and competition. It explores market size, revenue, production, consumption, and CAGR, using…
Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2023-203 …
DelveInsight's "Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hypertrophic Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypertrophic Cardiomyopathy Market Forecast
https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Hypertrophic Cardiomyopathy Market to Exhibit Rapid Growth Rate During the Forec …
DelveInsight's "Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hypertrophic Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypertrophic Cardiomyopathy Market Forecast
https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Hypertrophic Cardiomyopathy Market to Observe Impressive Growth During the Forec …
DelveInsight's "Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hypertrophic Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypertrophic Cardiomyopathy Market Forecast
https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Spinal Muscular Atrophy Therapeutics Pipeline Analysis with key Players Cytokine …
The study analyzed that the therapeutics pipeline comprises approximately 16 drug candidates in different stages of development.
Spinal muscular atrophy is defined as the inherited genetic disease that is characterized by a failure of nerve cells called motor neurons. Motor neurons are responsible to accept the nerve impulses transmitted from the brain to the spinal cord and transmit the impulses to the muscle with the help of peripheral nerves. The loss…
